Evidence map›Paper›PMID 29483648›Full record

ArticleNature structural & molecular biology2018

Screening, large-scale production and structure-based classification of cystine-dense peptides.

Colin E Correnti, Mesfin M Gewe, Christopher Mehlin, Ashok D Bandaranayake, William A Johnsen, Peter B Rupert, Mi-Youn Brusniak, Midori Clarke, Skyler E Burke, Willem De Van Der Schueren and 8 more

Abstract read
In one paragraph

Article in Nature structural & molecular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Facile, high-throughput protein purification enabled by high-efficiency protease elution.Protein science : a publication of the Protein Society · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Synthesis and preclinical evaluation of aEuropean journal of nuclear medicine and molecular imaging · 2025
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. An improved variant of tobacco etch virus (TEV) protease that does not need reducing agents.Protein science : a publication of the Protein Society · 2025
    Article
  11. The First KToxins · 2025
    Article
  12. Article
  13. Article
  14. Cnidarian toxins: omics approaches and recombinant proteins.The journal of venomous animals and toxins including tropical diseases · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Improving Protein Expression, Stability, and Function with ProteinMPNN.Journal of the American Chemical Society · 2024
    Article
  20. Siderocalin fusion proteins enable a newRSC chemical biology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Colin E CorrentiClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Mesfin M GeweClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Christopher MehlinClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Ashok D BandaranayakeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
William A JohnsenClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Peter B RupertBasic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Mi-Youn BrusniakClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0003-3950-1614
Midori ClarkeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-2402-108X
Skyler E BurkeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Willem De Van Der SchuerenClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Kristina PilatClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Shanon M TurnbaughClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Damon MayClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0001-6902-3153
Alex WatsonClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0003-0404-5735
Man Kid ChanClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-8133-9764
Christopher D BahlDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID 0000-0002-3652-3693
James M OlsonClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. jolson@fredhutch.org.
Roland K StrongBasic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. rstrong@fredhutch.org.ORCID 0000-0002-1338-2189

Funding

Chlorotoxin as a Targeting Agent for Cancer TherapiesR01CA135491 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OLSON, JAMES M · 2008 to 2018
$3.8M
Combinations of Synergistic Bispecific Human Antibodies: A Novel Strategy for the Treatment of NeuroblastomaU01CA232490 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI OLSON, JAMES M · 2018 to 2020
$2.4M
Pilatus 6mS10OD021832 · OD · UNIVERSITY OF CALIFORNIA BERKELEY · PI ADAMS, PAUL DAVID · 2016 to 2016
$980k
FHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600k
NCI NIH HHS R01 CA135491NCI NIH HHS U01 CA232490NIH HHS S10 OD020069NIH HHS S10 OD021832
6 · The paper itself

Abstract

Peptides folded through interwoven disulfides display extreme biochemical properties and unique medicinal potential. However, their exploitation has been hampered by the limited amounts isolatable from natural sources and the expense of chemical synthesis. We developed reliable biological methods for high-throughput expression, screening and large-scale production of these peptides: 46 were successfully produced in multimilligram quantities, and >600 more were deemed expressible through stringent screening criteria. Many showed extreme resistance to temperature, proteolysis and/or reduction, and all displayed inhibitory activity against at least 1 of 20 ion channels tested, thus confirming their biological functionality. Crystal structures of 12 confirmed proper cystine topology and the utility of crystallography to study these molecules but also highlighted the need for rational classification. Previous categorization attempts have focused on limited subsets featuring distinct motifs. Here we present a global definition, classification and analysis of >700 structures of cystine-dense peptides, providing a unifying framework for these molecules.

Indexed as

Amino Acid SequenceCrystallography, X-RayCystineHEK293 CellsHumansIon ChannelsModels, MolecularPeptide BiosynthesisPeptidesCystineIon ChannelsPeptides

Identifiers

PMID29483648
PMCPMC5840021

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.